{"protocolSection": {"identificationModule": {"nctId": "NCT00327015", "orgStudyIdInfo": {"id": "CV181-039"}, "organization": {"fullName": "AstraZeneca", "class": "INDUSTRY"}, "briefTitle": "A Phase 3 Study of BMS-477118 in Combination With Metformin in Subjects With Type 2 Diabetes Who Are Not Controlled With Diet and Exercise", "officialTitle": "A Multicenter, Randomized, Double-Blind Active-Controlled, Phase 3 Trial to Evaluate the Efficacy and Safety of Saxagliptin in Combination With Metformin IR as Initial Therapy Compared to Saxagliptin Monotherapy and to Metformin IR Monotherapy in Subjects With Type 2 Diabetes Who Have Inadequate Glycemic Control"}, "statusModule": {"statusVerifiedDate": "2015-03", "overallStatus": "COMPLETED", "expandedAccessInfo": {"hasExpandedAccess": false}, "startDateStruct": {"date": "2006-05"}, "primaryCompletionDateStruct": {"date": "2007-11", "type": "ACTUAL"}, "completionDateStruct": {"date": "2008-12", "type": "ACTUAL"}, "studyFirstSubmitDate": "2006-05-15", "studyFirstSubmitQcDate": "2006-05-15", "studyFirstPostDateStruct": {"date": "2006-05-17", "type": "ESTIMATED"}, "resultsFirstSubmitDate": "2009-08-17", "resultsFirstSubmitQcDate": "2009-08-17", "resultsFirstPostDateStruct": {"date": "2009-09-25", "type": "ESTIMATED"}, "lastUpdateSubmitDate": "2015-04-08", "lastUpdatePostDateStruct": {"date": "2015-04-29", "type": "ESTIMATED"}}, "sponsorCollaboratorsModule": {"responsibleParty": {"type": "SPONSOR"}, "leadSponsor": {"name": "AstraZeneca", "class": "INDUSTRY"}}, "oversightModule": {"oversightHasDmc": true}, "descriptionModule": {"briefSummary": "The purpose of this trial is to understand if adding saxagliptin to metformin therapy is safe and works better than taking either saxagliptin or metformin alone", "detailedDescription": "All subjects will participate in a lead-in period, and qualifying subjects will continue into a short-term randomized treatment period. Subjects who complete the short-term period will be eligible to enter the long term extension period. Also, subjects in the short-term period who have an elevated blood sugar that requires additional medication for blood sugar control will be eligible to enter the long-term treatment extension period where they will receive pioglitazone (rescue medication) added onto their blinded study medication"}, "conditionsModule": {"conditions": ["Diabetes"]}, "designModule": {"studyType": "INTERVENTIONAL", "phases": ["PHASE3"], "designInfo": {"allocation": "RANDOMIZED", "interventionModel": "PARALLEL", "primaryPurpose": "TREATMENT", "maskingInfo": {"masking": "DOUBLE", "whoMasked": ["PARTICIPANT", "INVESTIGATOR"]}}, "enrollmentInfo": {"count": 1306, "type": "ACTUAL"}}, "armsInterventionsModule": {"armGroups": [{"label": "Saxagliptin and Metformin (A)", "type": "EXPERIMENTAL", "description": "PLUS open-label pioglitazone (as needed as rescue medication)", "interventionNames": ["Drug: Saxagliptin", "Drug: Metformin", "Drug: pioglitazone"]}, {"label": "Saxagliptin and Metformin (B)", "type": "EXPERIMENTAL", "description": "PLUS open-label pioglitazone (as needed as rescue medication)", "interventionNames": ["Drug: Saxagliptin", "Drug: Metformin", "Drug: pioglitazone"]}, {"label": "Saxagliptin and Placebo (C)", "type": "EXPERIMENTAL", "description": "PLUS open-label pioglitazone (as needed as rescue medication)", "interventionNames": ["Drug: Saxagliptin", "Drug: Placebo", "Drug: pioglitazone"]}, {"label": "Metformin and Placebo (D)", "type": "ACTIVE_COMPARATOR", "description": "PLUS open-label pioglitazone (as needed as rescue medication)", "interventionNames": ["Drug: Metformin", "Drug: Placebo", "Drug: pioglitazone"]}], "interventions": [{"type": "DRUG", "name": "Saxagliptin", "description": "Coated Tablets, Oral, 10 mg, Daily (6 months ST, 12 months LT)", "armGroupLabels": ["Saxagliptin and Metformin (A)", "Saxagliptin and Placebo (C)"], "otherNames": ["BMS-477118"]}, {"type": "DRUG", "name": "Saxagliptin", "description": "Coated tablets, PO, 5 mg, Daily (6 months ST, 12 months LT)", "armGroupLabels": ["Saxagliptin and Metformin (B)"], "otherNames": ["BMS-477118"]}, {"type": "DRUG", "name": "Metformin", "description": "Coated tablets, Oral, 500 mg, Daily (6 months ST, 12 months LT)", "armGroupLabels": ["Metformin and Placebo (D)", "Saxagliptin and Metformin (A)", "Saxagliptin and Metformin (B)"]}, {"type": "DRUG", "name": "Placebo", "description": "Coated tablets, Oral, 0 mg, Daily (6 months ST, 12 months LT)", "armGroupLabels": ["Metformin and Placebo (D)", "Saxagliptin and Placebo (C)"]}, {"type": "DRUG", "name": "pioglitazone", "description": "Tablets, Oral, 15-45 mg, as needed (12 months LT)", "armGroupLabels": ["Metformin and Placebo (D)", "Saxagliptin and Metformin (A)", "Saxagliptin and Metformin (B)", "Saxagliptin and Placebo (C)"]}]}, "outcomesModule": {"primaryOutcomes": [{"measure": "Change From Baseline in Hemoglobin A1c (A1C) at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy", "description": "Mean change from baseline in A1C at Week 24, adjusted for baseline value.", "timeFrame": "Baseline, Week 24"}, {"measure": "Change From Baseline in A1C at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy", "description": "Mean change from baseline in A1C at Week 24, adjusted for baseline value.", "timeFrame": "Baseline, Week 24"}], "secondaryOutcomes": [{"measure": "Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy", "description": "Mean change from baseline in FPG at Week 24, adjusted for baseline value.", "timeFrame": "Baseline, Week 24"}, {"measure": "Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy", "description": "Mean change from baseline in FPG at Week 24, adjusted for baseline value.", "timeFrame": "Baseline, Week 24"}, {"measure": "Percentage of Participants Achieving A1C < 7% at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy", "description": "Percentage of participants achieving A1C \\< 7%, the American Diabetes Association's defined goal for glycemia, at each dose of saxagliptin plus metformin versus saxagliptin alone at Week 24.", "timeFrame": "Week 24"}, {"measure": "Percentage of Participants Achieving A1C < 7% at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy", "description": "Percentage of participants achieving A1C \\< 7%, the American Diabetes Association's defined goal for glycemia, at each dose of saxagliptin plus metformin versus metformin alone at Week 24.", "timeFrame": "Week 24"}, {"measure": "Changes From Baseline in Postprandial Glucose (PPG) Area Under the Curve (AUC) Response to an Oral Glucose Tolerance Test (OGTT) at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy", "description": "Mean change from baseline for 0 to 180 minutes PPG AUC at Week 24, adjusted for baseline value.", "timeFrame": "Baseline, Week 24"}, {"measure": "Changes From Baseline in Postprandial Glucose (PPG) Area Under the Curve (AUC) Response to an Oral Glucose Tolerance Test (OGTT) at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy", "description": "Mean change from baseline for 0 to 180 minutes PPG AUC at Week 24, adjsuted for baseline value.", "timeFrame": "Baseline, Week 24"}, {"measure": "Percentage of Participants Achieving A1C \u22646.5% at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy", "description": "Percentage of participants achieving A1C \u22646.5%, at each dose of saxagliptin plus metformin versus saxagliptin alone at Week 24.", "timeFrame": "Week 24"}, {"measure": "Percentage of Participants Achieving A1C \u22646.5% at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy", "description": "Percentage of participants achieving A1C \u22646.5%, at each dose of saxagliptin plus metformin versus metformin alone at Week 24.", "timeFrame": "Week 24"}, {"measure": "Percentage of Participants Requiring Rescue or Discontinuation at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy", "description": "Percentage of participants requiring rescue for failing to achieve pre-specified glycemic targets or discontinuing for lack of efficacy within the 24-week treatment period at each dose of saxagliptin plus metformin versus saxagliptin alone.", "timeFrame": "Week 24"}, {"measure": "Percentage of Participants Requiring Rescue or Discontinuation at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy", "description": "Percentage of participants requiring rescue for failing to achieve pre-specified glycemic targets or discontinuing for lack of efficacy within the 24-week treatment period at each dose of saxagliptin plus metformin versus metformin alone.", "timeFrame": "Week 24"}]}, "eligibilityModule": {"eligibilityCriteria": "Inclusion Criteria:\n\n* Type 2 diabetes\n* Inadequate blood sugar control\n* No current treatment with other medications to lower blood sugar\n\nExclusion Criteria:\n\n* Major heart, liver or kidney problems\n* Pregnant or breast feeding", "healthyVolunteers": false, "sex": "ALL", "minimumAge": "18 Years", "maximumAge": "77 Years", "stdAges": ["ADULT", "OLDER_ADULT"]}, "contactsLocationsModule": {"overallOfficials": [{"name": "Bristol-Myers Squibb", "affiliation": "Bristol-Myers Squibb", "role": "STUDY_DIRECTOR"}], "locations": [{"facility": "East Bay Clinical Trial Center", "city": "Concord", "state": "California", "zip": "94520", "country": "United States", "geoPoint": {"lat": 37.97798, "lon": -122.03107}}, {"facility": "Encompass Clinical Research", "city": "Encinitas", "state": "California", "zip": "92024", "country": "United States", "geoPoint": {"lat": 33.03699, "lon": -117.29198}}, {"facility": "Community Clinical Trials", "city": "Orange", "state": "California", "zip": "92868", "country": "United States", "geoPoint": {"lat": 33.78779, "lon": -117.85311}}, {"facility": "Coastal Biomedical Research Inc", "city": "Santa Monica", "state": "California", "zip": "90404", "country": "United States", "geoPoint": {"lat": 34.01945, "lon": -118.49119}}, {"facility": "Encompass Clinical Research", "city": "Spring Valley", "state": "California", "zip": "91978", "country": "United States", "geoPoint": {"lat": 32.74477, "lon": -116.99892}}, {"facility": "St. Joseph'S Medical Associates", "city": "Stockton", "state": "California", "zip": "95204", "country": "United States", "geoPoint": {"lat": 37.9577, "lon": -121.29078}}, {"facility": "Clinical Therapeutics Corporation", "city": "Coral Gables", "state": "Florida", "zip": "33134", "country": "United States", "geoPoint": {"lat": 25.72149, "lon": -80.26838}}, {"facility": "Florida Research Network, Llc", "city": "Gainesville", "state": "Florida", "zip": "32605", "country": "United States", "geoPoint": {"lat": 29.65163, "lon": -82.32483}}, {"facility": "Fpa Clinical Research", "city": "Kissimmee", "state": "Florida", "zip": "34741", "country": "United States", "geoPoint": {"lat": 28.30468, "lon": -81.41667}}, {"facility": "Emerald Coast Research Group", "city": "Marianna", "state": "Florida", "zip": "32446", "country": "United States", "geoPoint": {"lat": 30.77436, "lon": -85.22687}}, {"facility": "Baptist Diabetes Associates", "city": "Miami", "state": "Florida", "zip": "33156", "country": "United States", "geoPoint": {"lat": 25.77427, "lon": -80.19366}}, {"facility": "Middle Georgia Drug Study Center, Llc", "city": "Perry", "state": "Georgia", "zip": "31069", "country": "United States", "geoPoint": {"lat": 32.45821, "lon": -83.73157}}, {"facility": "Cedar Crosse Research Center", "city": "Chicago", "state": "Illinois", "zip": "60607", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Adviso Medical Research, Llc", "city": "Chicago", "state": "Illinois", "zip": "60617", "country": "United States", "geoPoint": {"lat": 41.85003, "lon": -87.65005}}, {"facility": "Deerbrook Medical Associates", "city": "Vernon Hills", "state": "Illinois", "zip": "60061", "country": "United States", "geoPoint": {"lat": 42.21947, "lon": -87.97952}}, {"facility": "Physicians Research Group", "city": "Indianapolis", "state": "Indiana", "zip": "46250", "country": "United States", "geoPoint": {"lat": 39.76838, "lon": -86.15804}}, {"facility": "Professional Network Research Of Kansas", "city": "Wichita", "state": "Kansas", "zip": "67203", "country": "United States", "geoPoint": {"lat": 37.69224, "lon": -97.33754}}, {"facility": "Medical Arts Research Collaborative, Llc", "city": "Excelsior Springs", "state": "Missouri", "zip": "64024", "country": "United States", "geoPoint": {"lat": 39.33917, "lon": -94.22606}}, {"facility": "Nevada Alliance Against Diabetes", "city": "N. Las Vegas", "state": "Nevada", "zip": "89030", "country": "United States", "geoPoint": {"lat": 36.19886, "lon": -115.1175}}, {"facility": "Metrolina Medical Research", "city": "Charlotte", "state": "North Carolina", "zip": "28209", "country": "United States", "geoPoint": {"lat": 35.22709, "lon": -80.84313}}, {"facility": "Durham Internal Medicine Assoc.", "city": "Durham", "state": "North Carolina", "zip": "27704", "country": "United States", "geoPoint": {"lat": 35.99403, "lon": -78.89862}}, {"facility": "Down East Medical Associates", "city": "Morehead City", "state": "North Carolina", "zip": "28557", "country": "United States", "geoPoint": {"lat": 34.72294, "lon": -76.72604}}, {"facility": "Midwest Regional Research, Inc.", "city": "Bellbrook", "state": "Ohio", "zip": "45305", "country": "United States", "geoPoint": {"lat": 39.63562, "lon": -84.07077}}, {"facility": "Massillon Family Practice", "city": "Massillon", "state": "Ohio", "zip": "44646", "country": "United States", "geoPoint": {"lat": 40.79672, "lon": -81.52151}}, {"facility": "Your Diabetes Endocrine Nutrition Group", "city": "Mentor", "state": "Ohio", "zip": "44060", "country": "United States", "geoPoint": {"lat": 41.66616, "lon": -81.33955}}, {"facility": "Newark Physician Associates", "city": "Newark", "state": "Ohio", "zip": "43055", "country": "United States", "geoPoint": {"lat": 40.05812, "lon": -82.40126}}, {"facility": "Preferred Primary Care Physicians", "city": "Uniontown", "state": "Pennsylvania", "zip": "15401", "country": "United States", "geoPoint": {"lat": 39.90008, "lon": -79.71643}}, {"facility": "Safe Harbor Clinical Research", "city": "E. Providence", "state": "Rhode Island", "zip": "02914", "country": "United States", "geoPoint": {"lat": 41.81371, "lon": -71.37005}}, {"facility": "Internal Medicine Of Greer", "city": "Greer", "state": "South Carolina", "zip": "29651", "country": "United States", "geoPoint": {"lat": 34.93873, "lon": -82.22706}}, {"facility": "Middle Tennessee Clinical Research", "city": "Fayetteville", "state": "Tennessee", "zip": "37334", "country": "United States", "geoPoint": {"lat": 35.15203, "lon": -86.57055}}, {"facility": "Frontier Clinical Research, Llc.", "city": "Memphis", "state": "Tennessee", "zip": "38103", "country": "United States", "geoPoint": {"lat": 35.14953, "lon": -90.04898}}, {"facility": "Capital Medical Clinic, Llp", "city": "Austin", "state": "Texas", "zip": "78705", "country": "United States", "geoPoint": {"lat": 30.26715, "lon": -97.74306}}, {"facility": "Endocrine Associates", "city": "Houston", "state": "Texas", "zip": "77004", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Advances In Health,Inc", "city": "Houston", "state": "Texas", "zip": "77030", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Juno Research, Llc", "city": "Houston", "state": "Texas", "zip": "77036", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Non Invasive Cardiovascular Pa", "city": "Houston", "state": "Texas", "zip": "77074", "country": "United States", "geoPoint": {"lat": 29.76328, "lon": -95.36327}}, {"facility": "Tiena Health Research", "city": "Irving", "state": "Texas", "zip": "75039", "country": "United States", "geoPoint": {"lat": 32.81402, "lon": -96.94889}}, {"facility": "Diabetes Center Of The Southwest", "city": "Midland", "state": "Texas", "zip": "79705", "country": "United States", "geoPoint": {"lat": 31.99735, "lon": -102.07791}}, {"facility": "Hill Country Medical Associates", "city": "New Braunfels", "state": "Texas", "zip": "78130", "country": "United States", "geoPoint": {"lat": 29.703, "lon": -98.12445}}, {"facility": "Pearland Primary Care Associates, Llp", "city": "Pearland", "state": "Texas", "zip": "77584", "country": "United States", "geoPoint": {"lat": 29.56357, "lon": -95.28605}}, {"facility": "Med-Cure Primary Care Physicians", "city": "Rosenberg", "state": "Texas", "zip": "77471", "country": "United States", "geoPoint": {"lat": 29.55718, "lon": -95.80856}}, {"facility": "Gsa Research", "city": "San Antonio", "state": "Texas", "zip": "78213", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Covenant Clinical Research, Pa", "city": "San Antonio", "state": "Texas", "zip": "78229", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "S.A.M. Clinical Research Center", "city": "San Antonio", "state": "Texas", "zip": "78229", "country": "United States", "geoPoint": {"lat": 29.42412, "lon": -98.49363}}, {"facility": "Seven Corners Medical Research Center", "city": "Falls Church", "state": "Virginia", "zip": "22044", "country": "United States", "geoPoint": {"lat": 38.88233, "lon": -77.17109}}, {"facility": "Salem Va Medical Ctr Research & Devlopment", "city": "Salem", "state": "Virginia", "zip": "24153", "country": "United States", "geoPoint": {"lat": 37.29347, "lon": -80.05476}}, {"facility": "Physicians Clinic Of Spokane", "city": "Spokane", "state": "Washington", "zip": "99204", "country": "United States", "geoPoint": {"lat": 47.65966, "lon": -117.42908}}, {"facility": "Local Institution", "city": "Belgrano", "state": "Buenos Aires", "zip": "C1426EGP", "country": "Argentina"}, {"facility": "Local Institution", "city": "Capital Federal", "state": "Buenos Aires", "zip": "1221", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Local Institution", "city": "Capital Federal", "state": "Buenos Aires", "zip": "C1406GWY", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Local Institution", "city": "Chacabuco", "state": "Buenos Aires", "zip": "6740", "country": "Argentina", "geoPoint": {"lat": -34.64167, "lon": -60.47389}}, {"facility": "Local Institution", "city": "La Plata", "state": "Buenos Aires", "zip": "B1902COS", "country": "Argentina", "geoPoint": {"lat": -34.92145, "lon": -57.95453}}, {"facility": "Local Institution", "city": "Moron", "state": "Buenos Aires", "zip": "B1708IFF", "country": "Argentina", "geoPoint": {"lat": -34.6509, "lon": -58.61956}}, {"facility": "Local Institution", "city": "San Martin", "state": "Buenos Aires", "zip": "CP1405", "country": "Argentina", "geoPoint": {"lat": -33.08103, "lon": -68.46814}}, {"facility": "Local Institution", "city": "San Pedro", "state": "Buenos Aires", "zip": "B2930DGO", "country": "Argentina", "geoPoint": {"lat": -24.23127, "lon": -64.86614}}, {"facility": "Local Institution", "city": "Zarate", "state": "Buenos Aires", "zip": "2800", "country": "Argentina", "geoPoint": {"lat": -34.09814, "lon": -59.02858}}, {"facility": "Local Institution", "city": "Rosario", "state": "Santa Fe", "zip": "CP2000", "country": "Argentina", "geoPoint": {"lat": -32.94682, "lon": -60.63932}}, {"facility": "Local Institution", "city": "Lanus Este", "state": "Tucuman", "zip": "1824", "country": "Argentina"}, {"facility": "Local Institution", "city": "Buenos Aires", "zip": "1121", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Local Institution", "city": "Buenos Aires", "zip": "B7602CBM", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Local Institution", "city": "Buenos Aires", "zip": "C1117ABH", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Local Institution", "city": "Buenos Aires", "zip": "C1408INH", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Local Institution", "city": "Buenos Aires", "zip": "C1425AGC", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Local Institution", "city": "Buenos Aires", "zip": "C1505CWB", "country": "Argentina", "geoPoint": {"lat": -34.61315, "lon": -58.37723}}, {"facility": "Local Institution", "city": "Mendoza", "zip": "CP5500", "country": "Argentina", "geoPoint": {"lat": -32.89084, "lon": -68.82717}}, {"facility": "Local Institution", "city": "Salta", "zip": "4406", "country": "Argentina", "geoPoint": {"lat": -24.7859, "lon": -65.41166}}, {"facility": "Local Institution", "city": "Salta", "zip": "A4400EMI", "country": "Argentina", "geoPoint": {"lat": -24.7859, "lon": -65.41166}}, {"facility": "Local Institution", "city": "San Juan", "zip": "5400", "country": "Argentina", "geoPoint": {"lat": -31.5375, "lon": -68.53639}}, {"facility": "Local Institution", "city": "Fortaleza", "state": "Ceara", "zip": "60021", "country": "Brazil", "geoPoint": {"lat": -3.71722, "lon": -38.54306}}, {"facility": "Local Institution", "city": "Fortaleza", "state": "Ceara", "zip": "60430", "country": "Brazil", "geoPoint": {"lat": -3.71722, "lon": -38.54306}}, {"facility": "Local Institution", "city": "Goiania", "state": "Goias", "zip": "74110", "country": "Brazil", "geoPoint": {"lat": -16.67861, "lon": -49.25389}}, {"facility": "Local Institution", "city": "Belem", "state": "Para", "zip": "66073", "country": "Brazil", "geoPoint": {"lat": -1.45583, "lon": -48.50444}}, {"facility": "Local Institution", "city": "Recife", "state": "Pe", "zip": "52051", "country": "Brazil", "geoPoint": {"lat": -8.05389, "lon": -34.88111}}, {"facility": "Local Institution", "city": "Porto Alegre", "state": "Rio Grande Do Sul", "zip": "90035", "country": "Brazil", "geoPoint": {"lat": -30.03306, "lon": -51.23}}, {"facility": "Local Institution", "city": "Campinas", "state": "Sao Paulo", "zip": "13059", "country": "Brazil", "geoPoint": {"lat": -22.90556, "lon": -47.06083}}, {"facility": "Local Institution", "city": "Mar\u00edlia", "state": "Sao Paulo", "zip": "17519", "country": "Brazil", "geoPoint": {"lat": -22.21389, "lon": -49.94583}}, {"facility": "Local Institution", "city": "Sao Paulo", "zip": "01244", "country": "Brazil", "geoPoint": {"lat": -23.5475, "lon": -46.63611}}, {"facility": "Local Institution", "city": "Sao Paulo", "zip": "04020", "country": "Brazil", "geoPoint": {"lat": -23.5475, "lon": -46.63611}}, {"facility": "Local Institution", "city": "Aschaffenburg", "zip": "63739", "country": "Germany", "geoPoint": {"lat": 49.97704, "lon": 9.15214}}, {"facility": "Local Institution", "city": "Bad", "zip": "37431", "country": "Germany", "geoPoint": {"lat": 47.63333, "lon": 9.83333}}, {"facility": "Local Institution", "city": "Dresden", "zip": "01307", "country": "Germany", "geoPoint": {"lat": 51.05089, "lon": 13.73832}}, {"facility": "Local Institution", "city": "Dresden", "zip": "O1219", "country": "Germany", "geoPoint": {"lat": 51.05089, "lon": 13.73832}}, {"facility": "Local Institution", "city": "Duisburg", "zip": "47051", "country": "Germany", "geoPoint": {"lat": 51.43247, "lon": 6.76516}}, {"facility": "Local Institution", "city": "Heidelberg", "zip": "69120", "country": "Germany", "geoPoint": {"lat": 49.40768, "lon": 8.69079}}, {"facility": "Local Institution", "city": "Kuenzing", "zip": "94550", "country": "Germany"}, {"facility": "Local Institution", "city": "Ludwigshafen", "zip": "67073", "country": "Germany", "geoPoint": {"lat": 49.48121, "lon": 8.44641}}, {"facility": "Local Institution", "city": "Magdeburg", "zip": "39112", "country": "Germany", "geoPoint": {"lat": 52.12773, "lon": 11.62916}}, {"facility": "Local Institution", "city": "Mainz", "zip": "55116", "country": "Germany", "geoPoint": {"lat": 49.98419, "lon": 8.2791}}, {"facility": "Local Institution", "city": "Mannheim", "zip": "68161", "country": "Germany", "geoPoint": {"lat": 49.4891, "lon": 8.46694}}, {"facility": "Local Institution", "city": "Saarbr\u00fccken", "zip": "66119", "country": "Germany", "geoPoint": {"lat": 49.23262, "lon": 7.0098}}, {"facility": "Local Institution", "city": "Vellmar", "zip": "34246", "country": "Germany", "geoPoint": {"lat": 51.35806, "lon": 9.47974}}, {"facility": "Local Institution", "city": "Wangen Im Allgau", "zip": "88239", "country": "Germany", "geoPoint": {"lat": 47.6895, "lon": 9.83247}}, {"facility": "Local Institution", "city": "Eger", "zip": "3300", "country": "Hungary", "geoPoint": {"lat": 47.90265, "lon": 20.37329}}, {"facility": "Local Institution", "city": "Gyula", "zip": "5700", "country": "Hungary", "geoPoint": {"lat": 46.65, "lon": 21.28333}}, {"facility": "Local Institution", "city": "Szentes", "zip": "6600", "country": "Hungary", "geoPoint": {"lat": 46.65628, "lon": 20.27194}}, {"facility": "Local Institution", "city": "Szigetv\u00e1r", "zip": "7900", "country": "Hungary", "geoPoint": {"lat": 46.04865, "lon": 17.80554}}, {"facility": "Local Institution", "city": "\u00c9rd", "zip": "2030", "country": "Hungary", "geoPoint": {"lat": 47.39489, "lon": 18.91361}}, {"facility": "Local Institution", "city": "Panjagutta, Hyderabad", "state": "Andhra Pradesh", "zip": "500082", "country": "India"}, {"facility": "Local Institution", "city": "Vasanth Nagar", "state": "Bangalore", "zip": "560052", "country": "India", "geoPoint": {"lat": 12.99182, "lon": 77.59444}}, {"facility": "Local Institution", "city": "Bangalore", "state": "Karnataka", "zip": "560010", "country": "India", "geoPoint": {"lat": 12.97194, "lon": 77.59369}}, {"facility": "Local Institution", "city": "Pune", "state": "Maharashtra", "zip": "411011", "country": "India", "geoPoint": {"lat": 18.51957, "lon": 73.85535}}, {"facility": "Local Institution", "city": "Kandivili West", "state": "Mumbai", "zip": "400067", "country": "India"}, {"facility": "Local Institution", "city": "Sarita Vihar", "state": "New Delhi", "zip": "110076", "country": "India"}, {"facility": "Local Institution", "city": "Chennai", "state": "Tamil Nadu", "zip": "680086", "country": "India", "geoPoint": {"lat": 13.08784, "lon": 80.27847}}, {"facility": "Local Institution", "city": "Bangalore", "zip": "560054", "country": "India", "geoPoint": {"lat": 12.97194, "lon": 77.59369}}, {"facility": "Local Institution", "city": "Chennai", "zip": "680004", "country": "India", "geoPoint": {"lat": 13.08784, "lon": 80.27847}}, {"facility": "Local Institution", "city": "Haryana", "zip": "132001", "country": "India", "geoPoint": {"lat": 29.61611, "lon": 76.98056}}, {"facility": "Local Institution", "city": "Rajasthan", "zip": "302001", "country": "India"}, {"facility": "Local Institution", "city": "Rajasthan", "zip": "334 003", "country": "India"}, {"facility": "Local Institution", "city": "Vellore, Tamilnadu", "zip": "632004", "country": "India"}, {"facility": "Local Institution", "city": "Catania", "zip": "20099", "country": "Italy", "geoPoint": {"lat": 37.49223, "lon": 15.07041}}, {"facility": "Local Institution", "city": "Genova", "zip": "16132", "country": "Italy", "geoPoint": {"lat": 44.40478, "lon": 8.94438}}, {"facility": "Local Institution", "city": "Milano", "zip": "20132", "country": "Italy", "geoPoint": {"lat": 45.46427, "lon": 9.18951}}, {"facility": "Local Institution", "city": "Perugia", "zip": "06124", "country": "Italy", "geoPoint": {"lat": 43.1122, "lon": 12.38878}}, {"facility": "Local Institution", "city": "Ravenna", "zip": "48100", "country": "Italy", "geoPoint": {"lat": 44.41344, "lon": 12.20121}}, {"facility": "Local Institution", "city": "Mexico", "state": "Distrito Federal", "zip": "06700", "country": "Mexico", "geoPoint": {"lat": 19.42847, "lon": -99.12766}}, {"facility": "Local Institution", "city": "Guadalajara", "state": "Jalisco", "zip": "44340", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "Local Institution", "city": "Guadalajara", "state": "Jalisco", "zip": "44650", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "Local Institution", "city": "Guadalajara", "state": "Jalisco", "zip": "44670", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "Local Institution", "city": "Guadalajara", "state": "Jalisco", "zip": "45030", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "Local Institution", "city": "Guadalajara", "state": "Jalisco", "zip": "45200", "country": "Mexico", "geoPoint": {"lat": 20.66682, "lon": -103.39182}}, {"facility": "Local Institution", "city": "Cuernavaca", "state": "Morelos", "zip": "62250", "country": "Mexico", "geoPoint": {"lat": 18.9261, "lon": -99.23075}}, {"facility": "Local Institution", "city": "Garza Garcia", "state": "Nuevo Leon", "zip": "66260", "country": "Mexico", "geoPoint": {"lat": 25.65384, "lon": -100.37758}}, {"facility": "Local Institution", "city": "Monterrey", "state": "Nuevo Leon", "zip": "64020", "country": "Mexico", "geoPoint": {"lat": 25.67507, "lon": -100.31847}}, {"facility": "Local Institution", "city": "Monterrey", "state": "Nuevo Leon", "zip": "64460", "country": "Mexico", "geoPoint": {"lat": 25.67507, "lon": -100.31847}}, {"facility": "Local Institution", "city": "Monterrey", "state": "Nuevo Leon", "zip": "64570", "country": "Mexico", "geoPoint": {"lat": 25.67507, "lon": -100.31847}}, {"facility": "Local Institution", "city": "Merida", "state": "Yucatan", "zip": "97070", "country": "Mexico", "geoPoint": {"lat": 20.97537, "lon": -89.61696}}, {"facility": "Local Institution", "city": "Aguascalientes", "zip": "20230", "country": "Mexico", "geoPoint": {"lat": 21.88234, "lon": -102.28259}}, {"facility": "Local Institution", "city": "Aguascalientes", "zip": "20232", "country": "Mexico", "geoPoint": {"lat": 21.88234, "lon": -102.28259}}, {"facility": "Local Institution", "city": "Cebu City", "zip": "6000", "country": "Philippines", "geoPoint": {"lat": 10.31672, "lon": 123.89071}}, {"facility": "Local Institution", "city": "Iloilo City", "zip": "5000", "country": "Philippines", "geoPoint": {"lat": 10.69694, "lon": 122.56444}}, {"facility": "Local Institution", "city": "Manila City", "zip": "1000", "country": "Philippines", "geoPoint": {"lat": 14.6042, "lon": 120.9822}}, {"facility": "Local Institution", "city": "Marikina City", "zip": "1800", "country": "Philippines", "geoPoint": {"lat": 14.6481, "lon": 121.1133}}, {"facility": "Local Institution", "city": "Pasig City", "zip": "1605", "country": "Philippines", "geoPoint": {"lat": 14.58691, "lon": 121.0614}}, {"facility": "Local Institution", "city": "Quezon City", "zip": "1100", "country": "Philippines", "geoPoint": {"lat": 14.6488, "lon": 121.0509}}, {"facility": "Local Institution", "city": "Gniewkowo", "zip": "88-140", "country": "Poland", "geoPoint": {"lat": 52.89461, "lon": 18.40785}}, {"facility": "Local Institution", "city": "Gorzow Wielkopolski", "zip": "66-400", "country": "Poland", "geoPoint": {"lat": 52.73679, "lon": 15.22878}}, {"facility": "Local Institution", "city": "Izabelin", "zip": "05-080", "country": "Poland", "geoPoint": {"lat": 52.29992, "lon": 20.81729}}, {"facility": "Local Institution", "city": "Krakow", "zip": "31-159", "country": "Poland", "geoPoint": {"lat": 50.06143, "lon": 19.93658}}, {"facility": "Local Institution", "city": "Lublin", "zip": "20-538", "country": "Poland", "geoPoint": {"lat": 51.25, "lon": 22.56667}}, {"facility": "Local Institution", "city": "Michalow-Regionow", "zip": "05-119", "country": "Poland"}, {"facility": "Local Institution", "city": "Warszawa", "zip": "03-563", "country": "Poland", "geoPoint": {"lat": 52.22977, "lon": 21.01178}}, {"facility": "Local Institution", "city": "Wroclaw", "zip": "50-127", "country": "Poland", "geoPoint": {"lat": 51.1, "lon": 17.03333}}, {"facility": "Local Institution", "city": "Zabrze", "zip": "41-800", "country": "Poland", "geoPoint": {"lat": 50.32492, "lon": 18.78576}}, {"facility": "Local Institution", "city": "Carolina", "zip": "00983", "country": "Puerto Rico", "geoPoint": {"lat": 18.38078, "lon": -65.95739}}, {"facility": "Local Institution", "city": "Ponce", "zip": "00716", "country": "Puerto Rico", "geoPoint": {"lat": 18.01108, "lon": -66.61406}}, {"facility": "Local Institution", "city": "Ponce", "zip": "00717", "country": "Puerto Rico", "geoPoint": {"lat": 18.01108, "lon": -66.61406}}, {"facility": "Local Institution", "city": "Rio Pieoras", "zip": "00926", "country": "Puerto Rico"}, {"facility": "Local Institution", "city": "San Juan", "zip": "00909", "country": "Puerto Rico", "geoPoint": {"lat": 18.46633, "lon": -66.10572}}, {"facility": "Local Institution", "city": "San Juan", "zip": "00920", "country": "Puerto Rico", "geoPoint": {"lat": 18.46633, "lon": -66.10572}}, {"facility": "Local Institution", "city": "Kemerovo", "state": "Russia", "zip": "650066", "country": "Russian Federation", "geoPoint": {"lat": 55.33333, "lon": 86.08333}}, {"facility": "Local Institution", "city": "Moscow", "state": "Russia", "zip": "117593", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Local Institution", "city": "Moscow", "state": "Russia", "zip": "123056", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Local Institution", "city": "Moscow", "state": "Russia", "zip": "125299", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Local Institution", "city": "Nizhniy Novgorod", "state": "Russia", "zip": "603018", "country": "Russian Federation", "geoPoint": {"lat": 56.32867, "lon": 44.00205}}, {"facility": "Local Institution", "city": "Izhevsk", "zip": "426000", "country": "Russian Federation", "geoPoint": {"lat": 56.84976, "lon": 53.20448}}, {"facility": "Local Institution", "city": "Kirov", "zip": "610030", "country": "Russian Federation", "geoPoint": {"lat": 58.59665, "lon": 49.66007}}, {"facility": "Local Institution", "city": "Krasnodar", "zip": "350012", "country": "Russian Federation", "geoPoint": {"lat": 45.04484, "lon": 38.97603}}, {"facility": "Local Institution", "city": "Krasnodar", "zip": "350042", "country": "Russian Federation", "geoPoint": {"lat": 45.04484, "lon": 38.97603}}, {"facility": "Local Institution", "city": "Kursk", "zip": "305035", "country": "Russian Federation", "geoPoint": {"lat": 51.73733, "lon": 36.18735}}, {"facility": "Local Institution", "city": "Moscow", "zip": "105229", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Local Institution", "city": "Moscow", "zip": "115093", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Local Institution", "city": "Moscow", "zip": "115280", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Local Institution", "city": "Moscow", "zip": "117292", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Local Institution", "city": "Moscow", "zip": "119034", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Local Institution", "city": "Moscow", "zip": "11992", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Local Institution", "city": "Moscow", "zip": "123423", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Local Institution", "city": "Moscow", "zip": "125315", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Local Institution", "city": "Moscow", "zip": "127486", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Local Institution", "city": "Moscow", "zip": "127644", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Local Institution", "city": "Moscow", "zip": "129010", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Local Institution", "city": "Moscow", "zip": "129119", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Local Institution", "city": "Moscow", "zip": "129327", "country": "Russian Federation", "geoPoint": {"lat": 55.75222, "lon": 37.61556}}, {"facility": "Local Institution", "city": "Nizhniy Novgorod", "zip": "603126", "country": "Russian Federation", "geoPoint": {"lat": 56.32867, "lon": 44.00205}}, {"facility": "Local Institution", "city": "Novosibirsk", "zip": "630047", "country": "Russian Federation", "geoPoint": {"lat": 55.0415, "lon": 82.9346}}, {"facility": "Local Institution", "city": "Novosibirsk", "zip": "630087", "country": "Russian Federation", "geoPoint": {"lat": 55.0415, "lon": 82.9346}}, {"facility": "Local Institution", "city": "Perm", "zip": "614095", "country": "Russian Federation", "geoPoint": {"lat": 58.01046, "lon": 56.25017}}, {"facility": "Local Institution", "city": "Rostov-Na-Donu", "zip": "344022", "country": "Russian Federation", "geoPoint": {"lat": 47.23135, "lon": 39.72328}}, {"facility": "Local Institution", "city": "Rostov-Na-Donu", "zip": "344029", "country": "Russian Federation", "geoPoint": {"lat": 47.23135, "lon": 39.72328}}, {"facility": "Local Institution", "city": "Saint Petersburg", "zip": "198013", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Local Institution", "city": "Saratov", "zip": "410024", "country": "Russian Federation", "geoPoint": {"lat": 51.54056, "lon": 46.00861}}, {"facility": "Local Institution", "city": "Saratov", "zip": "410028", "country": "Russian Federation", "geoPoint": {"lat": 51.54056, "lon": 46.00861}}, {"facility": "Local Institution", "city": "Saratov", "zip": "410053", "country": "Russian Federation", "geoPoint": {"lat": 51.54056, "lon": 46.00861}}, {"facility": "Local Institution", "city": "Saratov", "zip": "410054", "country": "Russian Federation", "geoPoint": {"lat": 51.54056, "lon": 46.00861}}, {"facility": "Local Institution", "city": "Smolensk", "zip": "214018", "country": "Russian Federation", "geoPoint": {"lat": 54.7818, "lon": 32.0401}}, {"facility": "Local Institution", "city": "St Petersburg", "zip": "193015", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Local Institution", "city": "St-Petersburg", "zip": "197022", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Local Institution", "city": "St. Peterburg", "zip": "195257", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Local Institution", "city": "St. Petersburg", "zip": "193312", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Local Institution", "city": "St. Petersburg", "zip": "195112", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Local Institution", "city": "St. Petersburg", "zip": "197198", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Local Institution", "city": "St.Petersburg", "zip": "191119", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Local Institution", "city": "St.Petersburg", "zip": "192177", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Local Institution", "city": "St.Petersburg", "zip": "194354", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Local Institution", "city": "St.Petersburg", "zip": "195176", "country": "Russian Federation", "geoPoint": {"lat": 59.93863, "lon": 30.31413}}, {"facility": "Local Institution", "city": "Tuymen", "zip": "625023", "country": "Russian Federation"}, {"facility": "Local Institution", "city": "Vladimir", "zip": "600023", "country": "Russian Federation", "geoPoint": {"lat": 56.13655, "lon": 40.39658}}, {"facility": "Local Institution", "city": "Volgograd", "zip": "400001", "country": "Russian Federation", "geoPoint": {"lat": 48.71939, "lon": 44.50183}}, {"facility": "Local Institution", "city": "Volgograd", "zip": "400107", "country": "Russian Federation", "geoPoint": {"lat": 48.71939, "lon": 44.50183}}, {"facility": "Local Institution", "city": "Yaroslaval", "zip": "150003", "country": "Russian Federation"}, {"facility": "Local Institution", "city": "Yaroslavl", "zip": "150003", "country": "Russian Federation", "geoPoint": {"lat": 57.62987, "lon": 39.87368}}, {"facility": "Local Institution", "city": "Dniepropetrovsk", "zip": "49044", "country": "Ukraine"}, {"facility": "Local Institution", "city": "Kharkiv", "zip": "61039", "country": "Ukraine", "geoPoint": {"lat": 49.98081, "lon": 36.25272}}, {"facility": "Local Institution", "city": "Kharkiv", "zip": "61176", "country": "Ukraine", "geoPoint": {"lat": 49.98081, "lon": 36.25272}}, {"facility": "Local Institution", "city": "Kyiv", "zip": "03680", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Local Institution", "city": "Kyiv", "zip": "4050", "country": "Ukraine", "geoPoint": {"lat": 50.45466, "lon": 30.5238}}, {"facility": "Local Institution", "city": "Lutsk", "zip": "43024", "country": "Ukraine", "geoPoint": {"lat": 50.75932, "lon": 25.34244}}, {"facility": "Local Institution", "city": "Lviv", "zip": "790015", "country": "Ukraine", "geoPoint": {"lat": 49.83826, "lon": 24.02324}}, {"facility": "Local Institution", "city": "Lviv", "zip": "79013", "country": "Ukraine", "geoPoint": {"lat": 49.83826, "lon": 24.02324}}, {"facility": "Local Institution", "city": "Odessa", "zip": "65025", "country": "Ukraine", "geoPoint": {"lat": 46.47747, "lon": 30.73262}}, {"facility": "Local Institution", "city": "Ternopil", "zip": "46001", "country": "Ukraine", "geoPoint": {"lat": 49.55589, "lon": 25.60556}}]}, "referencesModule": {"references": [{"pmid": "19515181", "type": "BACKGROUND", "citation": "Jadzinsky M, Pfutzner A, Paz-Pacheco E, Xu Z, Allen E, Chen R; CV181-039 Investigators. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab. 2009 Jun;11(6):611-22. doi: 10.1111/j.1463-1326.2009.01056.x."}, {"pmid": "32501595", "type": "DERIVED", "citation": "Gnesin F, Thuesen ACB, Kahler LKA, Madsbad S, Hemmingsen B. Metformin monotherapy for adults with type 2 diabetes mellitus. Cochrane Database Syst Rev. 2020 Jun 5;6(6):CD012906. doi: 10.1002/14651858.CD012906.pub2."}, {"pmid": "25414932", "type": "DERIVED", "citation": "Cook W, Minervini G, Bryzinski B, Hirshberg B. Saxagliptin efficacy and safety in patients with type 2 diabetes mellitus stratified by cardiovascular disease history and cardiovascular risk factors: analysis of 3 clinical trials. Postgrad Med. 2014 Oct;126(6):19-32. doi: 10.3810/pgm.2014.10.2818."}, {"pmid": "23795975", "type": "DERIVED", "citation": "Karyekar CS, Frederich R, Ravichandran S. Clinically relevant reductions in HbA1c without hypoglycaemia: results across four studies of saxagliptin. Int J Clin Pract. 2013 Aug;67(8):759-67. doi: 10.1111/ijcp.12212. Epub 2013 Jun 24."}, {"pmid": "21342412", "type": "DERIVED", "citation": "Pfutzner A, Paz-Pacheco E, Allen E, Frederich R, Chen R; CV181039 Investigators. Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes Obes Metab. 2011 Jun;13(6):567-76. doi: 10.1111/j.1463-1326.2011.01385.x."}]}}, "resultsSection": {"participantFlowModule": {"groups": [{"id": "FG000", "title": "Saxagliptin 5 mg + Metformin", "description": "The Saxagliptin 5 mg + Metformin group includes data from participants randomized to receive coadministration of blinded, fixed-dose saxagliptin 5 mg oral tablets and metformin IR 500 mg. Metformin Immediate Release (IR) was titrated, as tolerated, in increments of 500 mg up to a maximum of 2000 mg daily dose."}, {"id": "FG001", "title": "Saxagliptin 10 mg + Metformin", "description": "The Saxagliptin 10 mg + Metformin group includes data from participants randomized to receive coadministration of blinded, fixed-dose saxagliptin 10 mg oral tablets and metformin IR 500 mg. Metformin IR was titrated, as tolerated, in increments of 500 mg up to a maximum of 2000 mg daily dose."}, {"id": "FG002", "title": "Saxagliptin 10 mg", "description": "The Saxagliptin 10 mg group includes data from participants randomized to receive coadministration of blinded, fixed-dose saxagliptin 10 mg oral tablets and placebo resembling metformin."}, {"id": "FG003", "title": "Metformin", "description": "The Metformin group includes data from participants randomized to receive coadministration of metformin IR 500 mg. Metformin IR was titrated, as tolerated, in increments of 500 mg up to a maximum of 2000 mg daily dose and placebo resembling saxagliptin."}], "periods": [{"title": "Overall Study", "milestones": [{"type": "STARTED", "achievements": [{"groupId": "FG000", "numSubjects": "320"}, {"groupId": "FG001", "numSubjects": "323"}, {"groupId": "FG002", "numSubjects": "335"}, {"groupId": "FG003", "numSubjects": "328"}]}, {"type": "Completed Study Without Being Rescued", "achievements": [{"groupId": "FG000", "numSubjects": "179"}, {"groupId": "FG001", "numSubjects": "177"}, {"groupId": "FG002", "numSubjects": "113"}, {"groupId": "FG003", "numSubjects": "144"}]}, {"type": "COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "229"}, {"groupId": "FG001", "numSubjects": "231"}, {"groupId": "FG002", "numSubjects": "209"}, {"groupId": "FG003", "numSubjects": "219"}]}, {"type": "NOT COMPLETED", "achievements": [{"groupId": "FG000", "numSubjects": "91"}, {"groupId": "FG001", "numSubjects": "92"}, {"groupId": "FG002", "numSubjects": "126"}, {"groupId": "FG003", "numSubjects": "109"}]}], "dropWithdraws": [{"type": "Lack of Efficacy", "reasons": [{"groupId": "FG000", "numSubjects": "18"}, {"groupId": "FG001", "numSubjects": "18"}, {"groupId": "FG002", "numSubjects": "35"}, {"groupId": "FG003", "numSubjects": "29"}]}, {"type": "Withdrawal of Consent by Subject", "reasons": [{"groupId": "FG000", "numSubjects": "20"}, {"groupId": "FG001", "numSubjects": "24"}, {"groupId": "FG002", "numSubjects": "28"}, {"groupId": "FG003", "numSubjects": "25"}]}, {"type": "Lost to Follow-up", "reasons": [{"groupId": "FG000", "numSubjects": "22"}, {"groupId": "FG001", "numSubjects": "23"}, {"groupId": "FG002", "numSubjects": "29"}, {"groupId": "FG003", "numSubjects": "22"}]}, {"type": "Adverse Event", "reasons": [{"groupId": "FG000", "numSubjects": "14"}, {"groupId": "FG001", "numSubjects": "10"}, {"groupId": "FG002", "numSubjects": "14"}, {"groupId": "FG003", "numSubjects": "14"}]}, {"type": "Subject no longer meets study criteria", "reasons": [{"groupId": "FG000", "numSubjects": "4"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "8"}, {"groupId": "FG003", "numSubjects": "7"}]}, {"type": "Poor/Noncompliance", "reasons": [{"groupId": "FG000", "numSubjects": "11"}, {"groupId": "FG001", "numSubjects": "8"}, {"groupId": "FG002", "numSubjects": "4"}, {"groupId": "FG003", "numSubjects": "5"}]}, {"type": "Physician Decision", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "1"}, {"groupId": "FG002", "numSubjects": "3"}, {"groupId": "FG003", "numSubjects": "2"}]}, {"type": "Death", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "3"}]}, {"type": "Pregnancy", "reasons": [{"groupId": "FG000", "numSubjects": "0"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "1"}, {"groupId": "FG003", "numSubjects": "1"}]}, {"type": "Administrative Reason by Sponsor", "reasons": [{"groupId": "FG000", "numSubjects": "1"}, {"groupId": "FG001", "numSubjects": "2"}, {"groupId": "FG002", "numSubjects": "2"}, {"groupId": "FG003", "numSubjects": "1"}]}]}]}, "baselineCharacteristicsModule": {"groups": [{"id": "BG000", "title": "Saxagliptin 5 mg + Metformin", "description": "The Saxagliptin 5 mg + Metformin group includes data from participants randomized to receive coadministration of blinded, fixed-dose saxagliptin 5 mg oral tablets and metformin IR 500 mg. Metformin Immediate Release (IR) was titrated, as tolerated, in increments of 500 mg up to a maximum of 2000 mg daily dose."}, {"id": "BG001", "title": "Saxagliptin 10 mg + Metformin", "description": "The Saxagliptin 10 mg + Metformin group includes data from participants randomized to receive coadministration of blinded, fixed-dose saxagliptin 10 mg oral tablets and metformin IR 500 mg. Metformin IR was titrated, as tolerated, in increments of 500 mg up to a maximum of 2000 mg daily dose."}, {"id": "BG002", "title": "Saxagliptin 10 mg", "description": "The Saxagliptin 10 mg group includes data from participants randomized to receive coadministration of blinded, fixed-dose saxagliptin 10 mg oral tablets and placebo resembling metformin."}, {"id": "BG003", "title": "Metformin", "description": "The Metformin group includes data from participants randomized to receive coadministration of metformin IR 500 mg. Metformin IR was titrated, as tolerated, in increments of 500 mg up to a maximum of 2000 mg daily dose and placebo resembling saxagliptin."}, {"id": "BG004", "title": "Total", "description": "Total of all reporting groups"}], "denoms": [{"units": "Participants", "counts": [{"groupId": "BG000", "value": "320"}, {"groupId": "BG001", "value": "323"}, {"groupId": "BG002", "value": "335"}, {"groupId": "BG003", "value": "328"}, {"groupId": "BG004", "value": "1306"}]}], "measures": [{"title": "Age, Continuous", "paramType": "MEAN", "dispersionType": "STANDARD_DEVIATION", "unitOfMeasure": "years", "classes": [{"categories": [{"measurements": [{"groupId": "BG000", "value": "51.95", "spread": "10.43"}, {"groupId": "BG001", "value": "52.08", "spread": "11.59"}, {"groupId": "BG002", "value": "52.09", "spread": "10.17"}, {"groupId": "BG003", "value": "51.83", "spread": "10.74"}, {"groupId": "BG004", "value": "51.99", "spread": "10.73"}]}]}]}, {"title": "Sex: Female, Male", "paramType": "COUNT_OF_PARTICIPANTS", "unitOfMeasure": "Participants", "classes": [{"categories": [{"title": "Female", "measurements": [{"groupId": "BG000", "value": "155"}, {"groupId": "BG001", "value": "177"}, {"groupId": "BG002", "value": "166"}, {"groupId": "BG003", "value": "165"}, {"groupId": "BG004", "value": "663"}]}, {"title": "Male", "measurements": [{"groupId": "BG000", "value": "165"}, {"groupId": "BG001", "value": "146"}, {"groupId": "BG002", "value": "169"}, {"groupId": "BG003", "value": "163"}, {"groupId": "BG004", "value": "643"}]}]}]}]}, "outcomeMeasuresModule": {"outcomeMeasures": [{"type": "PRIMARY", "title": "Change From Baseline in Hemoglobin A1c (A1C) at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy", "description": "Mean change from baseline in A1C at Week 24, adjusted for baseline value.", "populationDescription": "Randomized participants who took at least 1 dose of double-blind treatment. To be included in analysis of change from baseline to Week 24 Last Observation Carried Forward (LOCF), subjects must have had a baseline and at least 1 post-baseline measurement. If participant received rescue medication, that measurement must have been taken before rescue.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percent", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Saxagliptin 5 mg + Metformin", "description": "The Saxagliptin 5 mg + Metformin group includes data from participants randomized to receive coadministration of blinded, fixed-dose saxagliptin 5 mg oral tablets and metformin IR 500 mg. Metformin IR was titrated, as tolerated, in increments of 500 mg up to a maximum of 2000 mg daily dose."}, {"id": "OG001", "title": "Saxagliptin 10 mg + Metformin", "description": "The Saxagliptin 10 mg + Metformin group includes data from participants randomized to receive coadministration of blinded, fixed-dose saxagliptin 10 mg oral tablets and metformin IR 500 mg. Metformin IR was titrated, as tolerated, in increments of 500 mg up to a maximum of 2000 mg daily dose."}, {"id": "OG002", "title": "Saxagliptin 10 mg", "description": "The Saxagliptin 10 mg group includes data from participants randomized to receive coadministration of blinded, fixed-dose saxagliptin 10 mg oral tablets and placebo resembling metformin."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "306"}, {"groupId": "OG001", "value": "315"}, {"groupId": "OG002", "value": "317"}]}], "classes": [{"title": "Baseline Mean", "categories": [{"measurements": [{"groupId": "OG000", "value": "9.41", "spread": "0.072"}, {"groupId": "OG001", "value": "9.53", "spread": "0.069"}, {"groupId": "OG002", "value": "9.61", "spread": "0.075"}]}]}, {"title": "Week 24 Mean", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.93", "spread": "0.066"}, {"groupId": "OG001", "value": "7.02", "spread": "0.067"}, {"groupId": "OG002", "value": "7.86", "spread": "0.085"}]}]}, {"title": "Adjusted Mean Change from Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.53", "spread": "0.070"}, {"groupId": "OG001", "value": "-2.49", "spread": "0.069"}, {"groupId": "OG002", "value": "-1.69", "spread": "0.069"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy", "description": "Mean change from baseline in FPG at Week 24, adjusted for baseline value.", "populationDescription": "Randomized participants who took at least 1 dose of double-blind treatment. To be included in analysis of change from baseline to Week 24 LOCF, participants must have had a baseline and at least 1 post-baseline measurement. If a participant received rescue medication, then that measurement must have been taken before rescue.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Saxagliptin 5 mg + Metformin", "description": "The Saxagliptin 5 mg + Metformin group includes data from participants randomized to receive coadministration of blinded, fixed-dose saxagliptin 5 mg oral tablets and metformin IR 500 mg. Metformin IR was titrated, as tolerated, in increments of 500 mg up to a maximum of 2000 mg daily dose."}, {"id": "OG001", "title": "Saxagliptin 10 mg + Metformin", "description": "The Saxagliptin 10 mg + Metformin group includes data from participants randomized to receive coadministration of blinded, fixed-dose saxagliptin 10 mg oral tablets and metformin IR 500 mg. Metformin IR was titrated, as tolerated, in increments of 500 mg up to a maximum of 2000 mg daily dose."}, {"id": "OG002", "title": "Saxagliptin 10 mg", "description": "The Saxagliptin 10 mg group includes data from participants randomized to receive coadministration of blinded, fixed-dose saxagliptin 10 mg oral tablets and placebo resembling metformin."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "315"}, {"groupId": "OG001", "value": "317"}, {"groupId": "OG002", "value": "327"}]}], "classes": [{"title": "Baseline Mean", "categories": [{"measurements": [{"groupId": "OG000", "value": "198.9", "spread": "3.17"}, {"groupId": "OG001", "value": "204.3", "spread": "3.35"}, {"groupId": "OG002", "value": "200.9", "spread": "3.03"}]}]}, {"title": "Week 24 Mean", "categories": [{"measurements": [{"groupId": "OG000", "value": "140.2", "spread": "2.39"}, {"groupId": "OG001", "value": "140.1", "spread": "2.34"}, {"groupId": "OG002", "value": "169.9", "spread": "3.20"}]}]}, {"title": "Adjusted Mean Change from Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-59.8", "spread": "2.34"}, {"groupId": "OG001", "value": "-62.2", "spread": "2.34"}, {"groupId": "OG002", "value": "-30.9", "spread": "2.30"}]}]}]}, {"type": "SECONDARY", "title": "Change From Baseline in Fasting Plasma Glucose (FPG) at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy", "description": "Mean change from baseline in FPG at Week 24, adjusted for baseline value.", "populationDescription": "Randomized participants who took at least 1 dose of double-blind treatment. To be included in analysis of change from baseline to Week 24 LOCF, participants must have had a baseline and at least 1 post-baseline measurement. If a participant received rescue medication, then that measurement must have been taken before rescue.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg/dL", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Saxagliptin 5 mg + Metformin", "description": "The Saxagliptin 5 mg + Metformin group includes data from participants randomized to receive coadministration of blinded, fixed-dose saxagliptin 5 mg oral tablets and metformin IR 500 mg. Metformin IR was titrated, as tolerated, in increments of 500 mg up to a maximum of 2000 mg daily dose."}, {"id": "OG001", "title": "Saxagliptin 10 mg + Metformin", "description": "The Saxagliptin 10 mg + Metformin group includes data from participants randomized to receive coadministration of blinded, fixed-dose saxagliptin 10 mg oral tablets and metformin IR 500 mg. Metformin IR was titrated, as tolerated, in increments of 500 mg up to a maximum of 2000 mg daily dose."}, {"id": "OG002", "title": "Metformin", "description": "The Metformin group includes data from participants randomized to receive coadministration of metformin IR 500 mg. Metformin IR was titrated, as tolerated, in increments of 500 mg up to a maximum of 2000 mg daily dose and placebo resembling saxagliptin."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "315"}, {"groupId": "OG001", "value": "317"}, {"groupId": "OG002", "value": "320"}]}], "classes": [{"title": "Baseline Mean", "categories": [{"measurements": [{"groupId": "OG000", "value": "198.9", "spread": "3.17"}, {"groupId": "OG001", "value": "204.3", "spread": "3.35"}, {"groupId": "OG002", "value": "199.1", "spread": "3.28"}]}]}, {"title": "Week 24 Mean", "categories": [{"measurements": [{"groupId": "OG000", "value": "140.2", "spread": "2.39"}, {"groupId": "OG001", "value": "140.1", "spread": "2.34"}, {"groupId": "OG002", "value": "152.7", "spread": "2.80"}]}]}, {"title": "Adjusted Mean Change from Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-59.8", "spread": "2.34"}, {"groupId": "OG001", "value": "-62.2", "spread": "2.34"}, {"groupId": "OG002", "value": "-47.3", "spread": "2.33"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants Achieving A1C < 7% at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy", "description": "Percentage of participants achieving A1C \\< 7%, the American Diabetes Association's defined goal for glycemia, at each dose of saxagliptin plus metformin versus saxagliptin alone at Week 24.", "populationDescription": "Randomized participants who took at least 1 dose of double-blind treatment. To be included in the Week 24 LOCF analysis, participants must have had at least 1 post-baseline measurement. If a participant received rescue medication, then that measurement must have been taken before rescue.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Week 24", "groups": [{"id": "OG000", "title": "Saxagliptin 5 mg + Metformin", "description": "The Saxagliptin 5 mg + Metformin group includes data from participants randomized to receive coadministration of blinded, fixed-dose saxagliptin 5 mg oral tablets and metformin IR 500 mg. Metformin IR was titrated, as tolerated, in increments of 500 mg up to a maximum of 2000 mg daily dose."}, {"id": "OG001", "title": "Saxagliptin 10 mg + Metformin", "description": "The Saxagliptin 10 mg + Metformin group includes data from participants randomized to receive coadministration of blinded, fixed-dose saxagliptin 10 mg oral tablets and metformin IR 500 mg. Metformin IR was titrated, as tolerated, in increments of 500 mg up to a maximum of 2000 mg daily dose."}, {"id": "OG002", "title": "Saxagliptin 10 mg", "description": "The Saxagliptin 10 mg group includes data from participants randomized to receive coadministration of blinded, fixed-dose saxagliptin 10 mg oral tablets and placebo resembling metformin."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "307"}, {"groupId": "OG001", "value": "315"}, {"groupId": "OG002", "value": "320"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "60.3"}, {"groupId": "OG001", "value": "59.7"}, {"groupId": "OG002", "value": "32.2"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants Achieving A1C < 7% at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy", "description": "Percentage of participants achieving A1C \\< 7%, the American Diabetes Association's defined goal for glycemia, at each dose of saxagliptin plus metformin versus metformin alone at Week 24.", "populationDescription": "Randomized participants who took at least 1 dose of double-blind treatment. To be included in the Week 24 LOCF analysis, participants must have had at least 1 post-baseline measurement. If a participant received rescue medication, then that measurement must have been taken before rescue.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Week 24", "groups": [{"id": "OG000", "title": "Saxagliptin 5 mg + Metformin", "description": "The Saxagliptin 5 mg + Metformin group includes data from participants randomized to receive coadministration of blinded, fixed-dose saxagliptin 5 mg oral tablets and metformin IR 500 mg. Metformin IR was titrated, as tolerated, in increments of 500 mg up to a maximum of 2000 mg daily dose."}, {"id": "OG001", "title": "Saxagliptin 10 mg + Metformin", "description": "The Saxagliptin 10 mg + Metformin group includes data from participants randomized to receive coadministration of blinded, fixed-dose saxagliptin 10 mg oral tablets and metformin IR 500 mg. Metformin IR was titrated, as tolerated, in increments of 500 mg up to a maximum of 2000 mg daily dose."}, {"id": "OG002", "title": "Metformin", "description": "The Metformin group includes data from participants randomized to receive coadministration of metformin IR 500 mg. Metformin IR was titrated, as tolerated, in increments of 500 mg up to a maximum of 2000 mg daily dose and placebo resembling saxagliptin."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "307"}, {"groupId": "OG001", "value": "315"}, {"groupId": "OG002", "value": "314"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "60.3"}, {"groupId": "OG001", "value": "59.7"}, {"groupId": "OG002", "value": "41.1"}]}]}]}, {"type": "SECONDARY", "title": "Changes From Baseline in Postprandial Glucose (PPG) Area Under the Curve (AUC) Response to an Oral Glucose Tolerance Test (OGTT) at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy", "description": "Mean change from baseline for 0 to 180 minutes PPG AUC at Week 24, adjusted for baseline value.", "populationDescription": "Randomized participants who took at least 1 dose of double-blind treatment. To be included in analysis of change from baseline to Week 24 LOCF, participants must have had a baseline and at least 1 post-baseline measurement. If a participant received rescue medication, then that measurement must have been taken before rescue.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg*min/dL", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Saxagliptin 5 mg + Metformin", "description": "The Saxagliptin 5 mg + Metformin group includes data from participants randomized to receive coadministration of blinded, fixed-dose saxagliptin 5 mg oral tablets and metformin IR 500 mg. Metformin IR was titrated, as tolerated, in increments of 500 mg up to a maximum of 2000 mg daily dose."}, {"id": "OG001", "title": "Saxagliptin 10 mg + Metformin", "description": "The Saxagliptin 10 mg + Metformin group includes data from participants randomized to receive coadministration of blinded, fixed-dose saxagliptin 10 mg oral tablets and metformin IR 500 mg. Metformin IR was titrated, as tolerated, in increments of 500 mg up to a maximum of 2000 mg daily dose."}, {"id": "OG002", "title": "Saxagliptin 10 mg", "description": "The Saxagliptin 10 mg group includes data from participants randomized to receive coadministration of blinded, fixed-dose saxagliptin 10 mg oral tablets and placebo resembling metformin."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "142"}, {"groupId": "OG001", "value": "131"}, {"groupId": "OG002", "value": "145"}]}], "classes": [{"title": "Baseline Mean", "categories": [{"measurements": [{"groupId": "OG000", "value": "55531", "spread": "1116.5"}, {"groupId": "OG001", "value": "57219", "spread": "1169.6"}, {"groupId": "OG002", "value": "57584", "spread": "1143.4"}]}]}, {"title": "Week 24 Mean", "categories": [{"measurements": [{"groupId": "OG000", "value": "35324", "spread": "890.0"}, {"groupId": "OG001", "value": "35790", "spread": "888.9"}, {"groupId": "OG002", "value": "41229", "spread": "1050.9"}]}]}, {"title": "Adjusted Mean Change from Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-21080", "spread": "836.5"}, {"groupId": "OG001", "value": "-21336", "spread": "869.6"}, {"groupId": "OG002", "value": "-16054", "spread": "826.7"}]}]}]}, {"type": "PRIMARY", "title": "Change From Baseline in A1C at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy", "description": "Mean change from baseline in A1C at Week 24, adjusted for baseline value.", "populationDescription": "Randomized participants who took at least 1 dose of double-blind treatment. To be included in analysis of change from baseline to Week 24 LOCF, participants must have had a baseline and at least 1 post-baseline measurement. If a participant received rescue medication, then that measurement must have been taken before rescue.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "percent", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Saxagliptin 5 mg + Metformin", "description": "The Saxagliptin 5 mg + Metformin group includes data from participants randomized to receive coadministration of blinded, fixed-dose saxagliptin 5 mg oral tablets and metformin IR 500 mg. Metformin IR was titrated, as tolerated, in increments of 500 mg up to a maximum of 2000 mg daily dose."}, {"id": "OG001", "title": "Saxagliptin 10 mg + Metformin", "description": "The Saxagliptin 10 mg + Metformin group includes data from participants randomized to receive coadministration of blinded, fixed-dose saxagliptin 10 mg oral tablets and metformin IR 500 mg. Metformin IR was titrated, as tolerated, in increments of 500 mg up to a maximum of 2000 mg daily dose."}, {"id": "OG002", "title": "Metformin", "description": "The Metformin group includes data from participants randomized to receive coadministration of metformin IR 500 mg. Metformin IR was titrated, as tolerated, in increments of 500 mg up to a maximum of 2000 mg daily dose and placebo resembling saxagliptin."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "306"}, {"groupId": "OG001", "value": "315"}, {"groupId": "OG002", "value": "313"}]}], "classes": [{"title": "Baseline Mean", "categories": [{"measurements": [{"groupId": "OG000", "value": "9.41", "spread": "0.072"}, {"groupId": "OG001", "value": "9.53", "spread": "0.069"}, {"groupId": "OG002", "value": "9.43", "spread": "0.073"}]}]}, {"title": "Week 24 Mean", "categories": [{"measurements": [{"groupId": "OG000", "value": "6.93", "spread": "0.066"}, {"groupId": "OG001", "value": "7.02", "spread": "0.067"}, {"groupId": "OG002", "value": "7.48", "spread": "0.084"}]}]}, {"title": "Adjusted Mean Change from Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-2.53", "spread": "0.070"}, {"groupId": "OG001", "value": "-2.49", "spread": "0.069"}, {"groupId": "OG002", "value": "-1.99", "spread": "0.069"}]}]}]}, {"type": "SECONDARY", "title": "Changes From Baseline in Postprandial Glucose (PPG) Area Under the Curve (AUC) Response to an Oral Glucose Tolerance Test (OGTT) at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy", "description": "Mean change from baseline for 0 to 180 minutes PPG AUC at Week 24, adjsuted for baseline value.", "populationDescription": "Randomized participants who took at least 1 dose of double-blind treatment. To be included in analysis of change from baseline to Week 24 LOCF, participants must have had a baseline and at least 1 post-baseline measurement. If a participant received rescue medication, then that measurement must have been taken before rescue.", "reportingStatus": "POSTED", "paramType": "MEAN", "dispersionType": "Standard Error", "unitOfMeasure": "mg*min/dL", "timeFrame": "Baseline, Week 24", "groups": [{"id": "OG000", "title": "Saxagliptin 5 mg + Metformin", "description": "The Saxagliptin 5 mg + Metformin group includes data from participants randomized to receive coadministration of blinded, fixed-dose saxagliptin 5 mg oral tablets and metformin IR 500 mg. Metformin IR was titrated, as tolerated, in increments of 500 mg up to a maximum of 2000 mg daily dose."}, {"id": "OG001", "title": "Saxagliptin 10 mg + Metformin", "description": "The Saxagliptin 10 mg + Metformin group includes data from participants randomized to receive coadministration of blinded, fixed-dose saxagliptin 10 mg oral tablets and metformin IR 500 mg. Metformin IR was titrated, as tolerated, in increments of 500 mg up to a maximum of 2000 mg daily dose."}, {"id": "OG002", "title": "Metformin", "description": "The Metformin group includes data from participants randomized to receive coadministration of metformin IR 500 mg. Metformin IR was titrated, as tolerated, in increments of 500 mg up to a maximum of 2000 mg daily dose and placebo resembling saxagliptin."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "142"}, {"groupId": "OG001", "value": "131"}, {"groupId": "OG002", "value": "135"}]}], "classes": [{"title": "Baseline Mean", "categories": [{"measurements": [{"groupId": "OG000", "value": "55531", "spread": "1116.5"}, {"groupId": "OG001", "value": "57219", "spread": "1169.6"}, {"groupId": "OG002", "value": "57937", "spread": "1281.7"}]}]}, {"title": "Week 24 Mean", "categories": [{"measurements": [{"groupId": "OG000", "value": "35324", "spread": "890.0"}, {"groupId": "OG001", "value": "35790", "spread": "888.9"}, {"groupId": "OG002", "value": "42428", "spread": "1082.1"}]}]}, {"title": "Adjusted Mean Change from Baseline", "categories": [{"measurements": [{"groupId": "OG000", "value": "-21080", "spread": "836.5"}, {"groupId": "OG001", "value": "-21336", "spread": "869.6"}, {"groupId": "OG002", "value": "-15005", "spread": "857.0"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants Achieving A1C \u22646.5% at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy", "description": "Percentage of participants achieving A1C \u22646.5%, at each dose of saxagliptin plus metformin versus saxagliptin alone at Week 24.", "populationDescription": "Randomized participants who took at least 1 dose of double-blind treatment. To be included in the Week 24 LOCF analysis, participants must have had at least 1 post-baseline measurement. If a participant received rescue medication, then that measurement must have been taken before rescue.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of Participants", "timeFrame": "Week 24", "groups": [{"id": "OG000", "title": "Saxagliptin 5 mg + Metformin", "description": "The Saxagliptin 5 mg + Metformin group includes data from participants randomized to receive coadministration of blinded, fixed-dose saxagliptin 5 mg oral tablets and metformin IR 500 mg. Metformin IR was titrated, as tolerated, in increments of 500 mg up to a maximum of 2000 mg daily dose."}, {"id": "OG001", "title": "Saxagliptin 10 mg + Metformin", "description": "The Saxagliptin 10 mg + Metformin group includes data from participants randomized to receive coadministration of blinded, fixed-dose saxagliptin 10 mg oral tablets and metformin IR 500 mg. Metformin IR was titrated, as tolerated, in increments of 500 mg up to a maximum of 2000 mg daily dose."}, {"id": "OG002", "title": "Saxagliptin 10 mg", "description": "The Saxagliptin 10 mg group includes data from participants randomized to receive coadministration of blinded, fixed-dose saxagliptin 10 mg oral tablets and placebo resembling metformin."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "307"}, {"groupId": "OG001", "value": "315"}, {"groupId": "OG002", "value": "320"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "45.3"}, {"groupId": "OG001", "value": "40.6"}, {"groupId": "OG002", "value": "20.3"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants Achieving A1C \u22646.5% at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy", "description": "Percentage of participants achieving A1C \u22646.5%, at each dose of saxagliptin plus metformin versus metformin alone at Week 24.", "populationDescription": "Randomized participants who took at least 1 dose of double-blind treatment. To be included in the Week 24 LOCF analysis, participants must have had at least 1 post-baseline measurement. If a participant received rescue medication, then that measurement must have been taken before rescue.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Week 24", "groups": [{"id": "OG000", "title": "Saxagliptin 5 mg + Metformin", "description": "The Saxagliptin 5 mg + Metformin group includes data from participants randomized to receive coadministration of blinded, fixed-dose saxagliptin 5 mg oral tablets and metformin IR 500 mg. Metformin IR was titrated, as tolerated, in increments of 500 mg up to a maximum of 2000 mg daily dose."}, {"id": "OG001", "title": "Saxagliptin 10 mg + Metformin", "description": "The Saxagliptin 10 mg + Metformin group includes data from participants randomized to receive coadministration of blinded, fixed-dose saxagliptin 10 mg oral tablets and metformin IR 500 mg. Metformin IR was titrated, as tolerated, in increments of 500 mg up to a maximum of 2000 mg daily dose."}, {"id": "OG002", "title": "Metformin", "description": "The Metformin group includes data from participants randomized to receive coadministration of metformin IR 500 mg. Metformin IR was titrated, as tolerated, in increments of 500 mg up to a maximum of 2000 mg daily dose and placebo resembling saxagliptin."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "307"}, {"groupId": "OG001", "value": "315"}, {"groupId": "OG002", "value": "314"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "45.3"}, {"groupId": "OG001", "value": "40.6"}, {"groupId": "OG002", "value": "29.0"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants Requiring Rescue or Discontinuation at Week 24, Saxagliptin Plus Metformin Versus Saxagliptin Monotherapy", "description": "Percentage of participants requiring rescue for failing to achieve pre-specified glycemic targets or discontinuing for lack of efficacy within the 24-week treatment period at each dose of saxagliptin plus metformin versus saxagliptin alone.", "populationDescription": "Randomized participants who took at least 1 dose of double-blind treatment were included in the Week 24 LOCF analysis.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Week 24", "groups": [{"id": "OG000", "title": "Saxagliptin 5 mg + Metformin", "description": "The Saxagliptin 5 mg + Metformin group includes data from participants randomized to receive coadministration of blinded, fixed-dose saxagliptin 5 mg oral tablets and metformin IR 500 mg. Metformin IR was titrated, as tolerated, in increments of 500 mg up to a maximum of 2000 mg daily dose."}, {"id": "OG001", "title": "Saxagliptin 10 mg + Metformin", "description": "The Saxagliptin 10 mg + Metformin group includes data from participants randomized to receive coadministration of blinded, fixed-dose saxagliptin 10 mg oral tablets and metformin IR 500 mg. Metformin IR was titrated, as tolerated, in increments of 500 mg up to a maximum of 2000 mg daily dose."}, {"id": "OG002", "title": "Saxagliptin 10 mg", "description": "The Saxagliptin 10 mg group includes data from participants randomized to receive coadministration of blinded, fixed-dose saxagliptin 10 mg oral tablets and placebo resembling metformin."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "320"}, {"groupId": "OG001", "value": "323"}, {"groupId": "OG002", "value": "335"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7.5"}, {"groupId": "OG001", "value": "5.9"}, {"groupId": "OG002", "value": "21.2"}]}]}]}, {"type": "SECONDARY", "title": "Percentage of Participants Requiring Rescue or Discontinuation at Week 24, Saxagliptin Plus Metformin Versus Metformin Monotherapy", "description": "Percentage of participants requiring rescue for failing to achieve pre-specified glycemic targets or discontinuing for lack of efficacy within the 24-week treatment period at each dose of saxagliptin plus metformin versus metformin alone.", "populationDescription": "Randomized participants who took at least 1 dose of double-blind treatment were included in the Week 24 LOCF analysis.", "reportingStatus": "POSTED", "paramType": "NUMBER", "unitOfMeasure": "Percentage of participants", "timeFrame": "Week 24", "groups": [{"id": "OG000", "title": "Saxagliptin 5 mg + Metformin", "description": "The Saxagliptin 5 mg + Metformin group includes data from participants randomized to receive coadministration of blinded, fixed-dose saxagliptin 5 mg oral tablets and metformin IR 500 mg. Metformin IR was titrated, as tolerated, in increments of 500 mg up to a maximum of 2000 mg daily dose."}, {"id": "OG001", "title": "Saxagliptin 10 mg + Metformin", "description": "The Saxagliptin 10 mg + Metformin group includes data from participants randomized to receive coadministration of blinded, fixed-dose saxagliptin 10 mg oral tablets and metformin IR 500 mg. Metformin IR was titrated, as tolerated, in increments of 500 mg up to a maximum of 2000 mg daily dose."}, {"id": "OG002", "title": "Metformin", "description": "The Metformin group includes data from participants randomized to receive coadministration of metformin IR 500 mg. Metformin IR was titrated, as tolerated, in increments of 500 mg up to a maximum of 2000 mg daily dose and placebo resembling saxagliptin."}], "denoms": [{"units": "Participants", "counts": [{"groupId": "OG000", "value": "320"}, {"groupId": "OG001", "value": "323"}, {"groupId": "OG002", "value": "328"}]}], "classes": [{"categories": [{"measurements": [{"groupId": "OG000", "value": "7.5"}, {"groupId": "OG001", "value": "5.9"}, {"groupId": "OG002", "value": "10.1"}]}]}]}]}, "adverseEventsModule": {"frequencyThreshold": "5", "eventGroups": [{"id": "EG000", "title": "Metformin", "description": "The Metformin group includes data from participants randomized to receive coadministration of metformin IR 500 mg. Metformin IR was titrated, as tolerated, in increments of 500 mg up to a maximum of 2000 mg daily dose and placebo resembling saxagliptin.", "seriousNumAffected": 15, "seriousNumAtRisk": 328, "otherNumAffected": 106, "otherNumAtRisk": 328}, {"id": "EG001", "title": "Saxagliptin 10 mg", "description": "The Saxagliptin 10 mg group includes data from participants randomized to receive coadministration of blinded, fixed-dose saxagliptin 10 mg oral tablets and placebo resembling metformin.", "seriousNumAffected": 16, "seriousNumAtRisk": 335, "otherNumAffected": 106, "otherNumAtRisk": 335}, {"id": "EG002", "title": "Saxagliptin 10 mg + Metformin", "description": "The Saxagliptin 10 mg + Metformin group includes data from participants randomized to receive coadministration of blinded, fixed-dose saxagliptin 10 mg oral tablets and metformin IR 500 mg. Metformin IR was titrated, as tolerated, in increments of 500 mg up to a maximum of 2000 mg daily dose.", "seriousNumAffected": 22, "seriousNumAtRisk": 323, "otherNumAffected": 122, "otherNumAtRisk": 323}, {"id": "EG003", "title": "Saxagliptin 5 mg + Metformin", "description": "The Saxagliptin 5 mg + Metformin group includes data from participants randomized to receive coadministration of blinded, fixed-dose saxagliptin 5 mg oral tablets and metformin IR 500 mg. Metformin IR was titrated, as tolerated, in increments of 500 mg up to a maximum of 2000 mg daily dose.", "seriousNumAffected": 16, "seriousNumAtRisk": 320, "otherNumAffected": 116, "otherNumAtRisk": 320}], "seriousEvents": [{"term": "DIABETIC RETINOPATHY", "organSystem": "Eye disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 320}]}, {"term": "CARDIAC ARREST", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 320}]}, {"term": "CARDIAC FAILURE", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 320}]}, {"term": "ATRIAL FIBRILLATION", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 320}]}, {"term": "CARDIAC FAILURE ACUTE", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 320}]}, {"term": "MYOCARDIAL INFARCTION", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 2, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 320}]}, {"term": "CORONARY ARTERY DISEASE", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 320}]}, {"term": "ACUTE MYOCARDIAL INFARCTION", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 2, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 320}]}, {"term": "ARTERIOSCLEROSIS CORONARY ARTERY", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 320}]}, {"term": "ATRIOVENTRICULAR BLOCK SECOND DEGREE", "organSystem": "Cardiac disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 320}]}, {"term": "EXTREMITY NECROSIS", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 320}]}, {"term": "DIABETIC MACROANGIOPATHY", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 320}]}, {"term": "CHOLECYSTITIS", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 320}]}, {"term": "CHOLELITHIASIS", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 320}]}, {"term": "CHOLECYSTITIS ACUTE", "organSystem": "Hepatobiliary disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 320}]}, {"term": "SCIATICA", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 320}]}, {"term": "ISCHAEMIC STROKE", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 320}]}, {"term": "SYNCOPE VASOVAGAL", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 320}]}, {"term": "CEREBRAL INFARCTION", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 320}]}, {"term": "HAEMORRHAGIC STROKE", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 320}]}, {"term": "FACIAL NERVE DISORDER", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 320}]}, {"term": "CEREBROVASCULAR ACCIDENT", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 320}]}, {"term": "TRANSIENT ISCHAEMIC ATTACK", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 320}]}, {"term": "GASTRITIS", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 320}]}, {"term": "PANCREATITIS", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 320}]}, {"term": "HIATUS HERNIA", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 320}]}, {"term": "FOOD POISONING", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 320}]}, {"term": "GASTRIC POLYPS", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 320}]}, {"term": "INGUINAL HERNIA", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 320}]}, {"term": "UMBILICAL HERNIA", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 320}]}, {"term": "GASTRITIS EROSIVE", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 320}]}, {"term": "PANCREATITIS ACUTE", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 320}]}, {"term": "DEAFNESS", "organSystem": "Ear and labyrinth disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 320}]}, {"term": "SEPSIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 320}]}, {"term": "TETANUS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 320}]}, {"term": "PNEUMONIA", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 320}]}, {"term": "ERYSIPELAS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 320}]}, {"term": "APPENDICITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 320}]}, {"term": "GASTROENTERITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 320}]}, {"term": "SCROTAL ABSCESS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 320}]}, {"term": "PHARYNGOTONSILLITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 320}]}, {"term": "NEPHROLITHIASIS", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 320}]}, {"term": "RENAL FAILURE ACUTE", "organSystem": "Renal and urinary disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 320}]}, {"term": "DEHYDRATION", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 320}]}, {"term": "HYPERKALAEMIA", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 320}]}, {"term": "DIABETES MELLITUS", "organSystem": "Metabolism and nutrition disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 320}]}, {"term": "LYMPHOPENIA", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 320}]}, {"term": "LYMPHADENITIS", "organSystem": "Blood and lymphatic system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 320}]}, {"term": "ROSACEA", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 320}]}, {"term": "INGROWING NAIL", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 320}]}, {"term": "DERMATITIS ALLERGIC", "organSystem": "Skin and subcutaneous tissue disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 320}]}, {"term": "MENOMETRORRHAGIA", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 320}]}, {"term": "ACQUIRED PHIMOSIS", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 320}]}, {"term": "UTERINE HAEMORRHAGE", "organSystem": "Reproductive system and breast disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 320}]}, {"term": "ACCIDENT", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 320}]}, {"term": "OVERDOSE", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 320}]}, {"term": "WRIST FRACTURE", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 320}]}, {"term": "LOWER LIMB FRACTURE", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 320}]}, {"term": "UPPER LIMB FRACTURE", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 320}]}, {"term": "ROAD TRAFFIC ACCIDENT", "organSystem": "Injury, poisoning and procedural complications", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 320}]}, {"term": "BACK PAIN", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 320}]}, {"term": "OSTEOARTHRITIS", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 320}]}, {"term": "OSTEOCHONDROSIS", "organSystem": "Musculoskeletal and connective tissue disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 320}]}, {"term": "LUNG CONSOLIDATION", "organSystem": "Respiratory, thoracic and mediastinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 1, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 320}]}, {"term": "PYREXIA", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 320}]}, {"term": "SUDDEN DEATH", "organSystem": "General disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 320}]}, {"term": "PAPILLOMA", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 1, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 320}]}, {"term": "BILE DUCT CANCER", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 320}]}, {"term": "PANCREATIC NEOPLASM", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 1, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 0, "numAtRisk": 320}]}, {"term": "LYMPHOPROLIFERATIVE DISORDER", "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 0, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 0, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 0, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 1, "numAtRisk": 320}]}], "otherEvents": [{"term": "HYPERTENSION", "organSystem": "Vascular disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 17, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 19, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 21, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 27, "numAtRisk": 320}]}, {"term": "HEADACHE", "organSystem": "Nervous system disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 18, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 31, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 36, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 31, "numAtRisk": 320}]}, {"term": "DIARRHOEA", "organSystem": "Gastrointestinal disorders", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 30, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 12, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 41, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 26, "numAtRisk": 320}]}, {"term": "INFLUENZA", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 19, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 17, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 13, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 20, "numAtRisk": 320}]}, {"term": "NASOPHARYNGITIS", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 19, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 24, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 19, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 29, "numAtRisk": 320}]}, {"term": "URINARY TRACT INFECTION", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 25, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 23, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 22, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 13, "numAtRisk": 320}]}, {"term": "UPPER RESPIRATORY TRACT INFECTION", "organSystem": "Infections and infestations", "sourceVocabulary": "MedDRA 11.1", "assessmentType": "SYSTEMATIC_ASSESSMENT", "stats": [{"groupId": "EG000", "numAffected": 10, "numAtRisk": 328}, {"groupId": "EG001", "numAffected": 14, "numAtRisk": 335}, {"groupId": "EG002", "numAffected": 19, "numAtRisk": 323}, {"groupId": "EG003", "numAffected": 15, "numAtRisk": 320}]}]}, "moreInfoModule": {"certainAgreement": {"piSponsorEmployee": false, "restrictionType": "OTHER", "restrictiveAgreement": true, "otherDetails": "Bristol-Myers Squibb Co. agreements with investigators vary; constant is our right to embargo communications regarding trial results prior to public release for a period \u226460 days from submittal for review. We will not prohibit investigators from publishing, but will prohibit the disclosure of previously undisclosed confidential information other than study results, and request postponement of single-center publications until after disclosure of the clinical trial's primary publication."}, "pointOfContact": {"title": "Boaz Hirschberg", "organization": "AstraZeneca Pharmaceuticals", "email": "ClinicalTrialTransparency@astrazeneca.com"}}}, "derivedSection": {"miscInfoModule": {"versionHolder": "2024-06-24"}, "conditionBrowseModule": {"meshes": [{"id": "D000003920", "term": "Diabetes Mellitus"}], "ancestors": [{"id": "D000044882", "term": "Glucose Metabolism Disorders"}, {"id": "D000008659", "term": "Metabolic Diseases"}, {"id": "D000004700", "term": "Endocrine System Diseases"}], "browseLeaves": [{"id": "M7115", "name": "Diabetes Mellitus", "asFound": "Diabetes", "relevance": "HIGH"}, {"id": "M7119", "name": "Diabetes Mellitus, Type 2", "relevance": "LOW"}, {"id": "M11639", "name": "Metabolic Diseases", "relevance": "LOW"}, {"id": "M25403", "name": "Glucose Metabolism Disorders", "relevance": "LOW"}, {"id": "M7862", "name": "Endocrine System Diseases", "relevance": "LOW"}], "browseBranches": [{"abbrev": "BC18", "name": "Nutritional and Metabolic Diseases"}, {"abbrev": "BC19", "name": "Gland and Hormone Related Diseases"}, {"abbrev": "All", "name": "All Conditions"}]}, "interventionBrowseModule": {"meshes": [{"id": "D000008687", "term": "Metformin"}, {"id": "D000077205", "term": "Pioglitazone"}, {"id": "C000502994", "term": "Saxagliptin"}], "ancestors": [{"id": "D000007004", "term": "Hypoglycemic Agents"}, {"id": "D000045505", "term": "Physiological Effects of Drugs"}, {"id": "D000054795", "term": "Incretins"}, {"id": "D000006728", "term": "Hormones"}, {"id": "D000006730", "term": "Hormones, Hormone Substitutes, and Hormone Antagonists"}, {"id": "D000054873", "term": "Dipeptidyl-Peptidase IV Inhibitors"}, {"id": "D000011480", "term": "Protease Inhibitors"}, {"id": "D000004791", "term": "Enzyme Inhibitors"}, {"id": "D000045504", "term": "Molecular Mechanisms of Pharmacological Action"}], "browseLeaves": [{"id": "M11667", "name": "Metformin", "asFound": "Assessment", "relevance": "HIGH"}, {"id": "M1693", "name": "Pioglitazone", "asFound": "Registry", "relevance": "HIGH"}, {"id": "M228152", "name": "Saxagliptin", "asFound": "Manufacturer", "relevance": "HIGH"}, {"id": "M10054", "name": "Hypoglycemic Agents", "relevance": "LOW"}, {"id": "M27905", "name": "Incretins", "relevance": "LOW"}, {"id": "M9789", "name": "Hormones", "relevance": "LOW"}, {"id": "M9788", "name": "Hormone Antagonists", "relevance": "LOW"}, {"id": "M27957", "name": "Dipeptidyl-Peptidase IV Inhibitors", "relevance": "LOW"}, {"id": "M19609", "name": "HIV Protease Inhibitors", "relevance": "LOW"}, {"id": "M14343", "name": "Protease Inhibitors", "relevance": "LOW"}, {"id": "M7951", "name": "Enzyme Inhibitors", "relevance": "LOW"}], "browseBranches": [{"abbrev": "Hypo", "name": "Hypoglycemic Agents"}, {"abbrev": "All", "name": "All Drugs and Chemicals"}, {"abbrev": "Infe", "name": "Anti-Infective Agents"}]}}, "hasResults": true}